Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04722575
Title Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fondazione Melanoma Onlus
Indications

melanoma

Therapies

Atezolizumab + Cobimetinib + Vemurafenib

Atezolizumab + Cobimetinib

Age Groups: adult | senior
Covered Countries


No variant requirements are available.